PL2170340T3 - Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów - Google Patents
Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonówInfo
- Publication number
- PL2170340T3 PL2170340T3 PL08771642T PL08771642T PL2170340T3 PL 2170340 T3 PL2170340 T3 PL 2170340T3 PL 08771642 T PL08771642 T PL 08771642T PL 08771642 T PL08771642 T PL 08771642T PL 2170340 T3 PL2170340 T3 PL 2170340T3
- Authority
- PL
- Poland
- Prior art keywords
- isothiazolopyrimidinones
- compositions
- methods
- neuronal degeneration
- inhibiting neuronal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94552407P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067742 WO2008157791A2 (en) | 2007-06-21 | 2008-06-20 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| EP08771642.9A EP2170340B1 (en) | 2007-06-21 | 2008-06-20 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2170340T3 true PL2170340T3 (pl) | 2016-06-30 |
Family
ID=40156978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08771642T PL2170340T3 (pl) | 2007-06-21 | 2008-06-20 | Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008265600B2 (en) * | 2007-06-21 | 2013-10-31 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| AU2010298440B2 (en) * | 2009-09-22 | 2016-05-19 | Neuronascent, Inc | Methods and pharmaceutical compositions for treating down syndrome |
| AU2013207796B2 (en) | 2012-01-13 | 2017-04-27 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| ES2705247T3 (es) * | 2013-03-14 | 2019-03-22 | Univ Columbia | 4-fenilpiperidinas, su preparación y uso |
| WO2014151959A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| US9637450B2 (en) | 2013-03-14 | 2017-05-02 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
| CN111393434B (zh) | 2014-04-30 | 2022-11-04 | 哥伦比亚大学董事会 | 取代的4-苯基哌啶及其制备和用途 |
| RU2613765C1 (ru) * | 2016-01-26 | 2017-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" | Способ лечения спиноцеребеллярной атаксии |
| US10064833B2 (en) * | 2016-08-04 | 2018-09-04 | Syneurx International (Taiwan) Corp. | Compositions containing benzoate compound and tannic acid for treating central nervous system disorders |
| RU2670128C2 (ru) * | 2016-12-16 | 2018-10-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов |
| RU2675111C2 (ru) * | 2017-03-31 | 2018-12-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Способ стимуляции нейрогенеза в гиппокампе |
| EP3648605A1 (en) * | 2017-07-03 | 2020-05-13 | Bayer CropScience Aktiengesellschaft | Novel isothiazolo-based bicycles, processes for their preparation and their use as herbicides and/or plant growth regulators |
| WO2019237125A1 (en) | 2018-06-08 | 2019-12-12 | The General Hospital Corporation | Inhibitors of prolyl-trna-synthetase |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CH588887A5 (US20100298318A1-20101125-C00013.png) | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
| US4089809A (en) | 1976-03-01 | 1978-05-16 | The United States Of America As Represented By The United States Department Of Energy | Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures |
| US4233871A (en) | 1978-04-26 | 1980-11-18 | Alessi Anthony A | Notching tool |
| ATE8584T1 (de) | 1980-01-16 | 1984-08-15 | Hans Georg Prof. Dr. Weder | Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel. |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4532089A (en) | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
| US4897269A (en) | 1984-09-24 | 1990-01-30 | Mezei Associates Limited | Administration of drugs with multiphase liposomal delivery system |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5820880A (en) | 1995-06-07 | 1998-10-13 | The United States Of America As Represented By The Secretary Of The Army | Liposomal formulation |
| US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| AU4709400A (en) | 1999-05-11 | 2000-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| MXPA05009577A (es) * | 2003-03-07 | 2005-12-12 | Astrazeneca Ab | Heterociclos fundidos novedosos y sus usos. |
| ATE475421T1 (de) * | 2003-05-06 | 2010-08-15 | Ustav Ex Botan Akademie Ved Ce | Pyrazoloä4,3-düpyrimidines, verfahren zur ihre herstellung und deren verwendung |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| EP1781673B1 (en) * | 2004-08-18 | 2009-10-21 | AstraZeneca AB | Selected fused heterocyclics and uses thereof |
| CA2621560A1 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| AU2008265600B2 (en) * | 2007-06-21 | 2013-10-31 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
-
2008
- 2008-06-20 AU AU2008265600A patent/AU2008265600B2/en active Active
- 2008-06-20 DK DK08771642.9T patent/DK2170340T3/en active
- 2008-06-20 ES ES08771642.9T patent/ES2564826T3/es active Active
- 2008-06-20 CN CN200880021069A patent/CN101842100A/zh active Pending
- 2008-06-20 EP EP16155774.9A patent/EP3053584A1/en not_active Withdrawn
- 2008-06-20 RU RU2010100945/15A patent/RU2521333C2/ru active
- 2008-06-20 JP JP2010513461A patent/JP2010530898A/ja active Pending
- 2008-06-20 KR KR1020107001298A patent/KR101565971B1/ko active IP Right Grant
- 2008-06-20 EP EP08771642.9A patent/EP2170340B1/en active Active
- 2008-06-20 US US12/664,995 patent/US8609840B2/en active Active
- 2008-06-20 WO PCT/US2008/067742 patent/WO2008157791A2/en active Application Filing
- 2008-06-20 KR KR1020157008401A patent/KR101600054B1/ko active IP Right Grant
- 2008-06-20 CA CA2693062A patent/CA2693062C/en active Active
- 2008-06-20 PL PL08771642T patent/PL2170340T3/pl unknown
-
2009
- 2009-12-03 IL IL202485A patent/IL202485A/en not_active IP Right Cessation
-
2013
- 2013-11-13 US US14/079,489 patent/US9096613B2/en active Active
-
2014
- 2014-05-15 JP JP2014101014A patent/JP5850981B2/ja active Active
-
2015
- 2015-06-16 JP JP2015121083A patent/JP6081528B2/ja active Active
- 2015-06-26 US US14/751,403 patent/US9592234B2/en active Active
-
2017
- 2017-01-18 JP JP2017006944A patent/JP2017066166A/ja active Pending
- 2017-03-14 IL IL251169A patent/IL251169A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251169A0 (en) | Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones | |
| HRP20182135T1 (hr) | Pripravci za i postupci liječenja poremećaja povezanih s ige | |
| HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
| EP2170309A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| ZA201001810B (en) | Seed treatment compositions and methods | |
| ZA201001811B (en) | Seed treatment compositions and methods | |
| EP2176283A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES | |
| EP2150117A4 (en) | METHOD AND COMPOSITIONS FOR MITOCHONDRIAL SPARE THERAPY | |
| IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
| HK1148906A1 (en) | Compositions and methods for cancer treatment | |
| HK1145339A1 (zh) | 用於定向整合的方法和組合物 | |
| IL202329A0 (en) | Methods and compositions for stimulating cells | |
| IL202015A0 (en) | Methods and compositions for treating skin conditions | |
| EP2120561A4 (en) | COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE | |
| PL2187880T3 (pl) | Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej | |
| EP1937252A4 (en) | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | |
| EP2205255A4 (en) | VEGETABLE COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEPATITIC ILLNESSES | |
| EP2124991A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING EFFECTIVE DYSFUNCTION | |
| HRP20130642T1 (en) | Methods and compositions for treating cancers | |
| IL173971A0 (en) | Compositions and methods for treating and preventing age-related macular degeneration | |
| EP2237777A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| GB0419295D0 (en) | Methods and compositions to prevent neuronal degeneration | |
| GB0714500D0 (en) | composition and treatment | |
| EP2278982A4 (en) | COMPOSITIONS AND METHODS OF TREATING NEURODEEGENERATIVE ILLNESSES | |
| GB0504057D0 (en) | Methods and compositions to prevent neuronal degeneration |